1. Home
  2. MDWD vs VSTA Comparison

MDWD vs VSTA Comparison

Compare MDWD & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • VSTA
  • Stock Information
  • Founded
  • MDWD 2000
  • VSTA 1966
  • Country
  • MDWD Israel
  • VSTA Brazil
  • Employees
  • MDWD N/A
  • VSTA N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • VSTA Other Consumer Services
  • Sector
  • MDWD Health Care
  • VSTA Real Estate
  • Exchange
  • MDWD Nasdaq
  • VSTA Nasdaq
  • Market Cap
  • MDWD 184.8M
  • VSTA 187.6M
  • IPO Year
  • MDWD 2014
  • VSTA 2020
  • Fundamental
  • Price
  • MDWD $19.45
  • VSTA $2.83
  • Analyst Decision
  • MDWD Strong Buy
  • VSTA Sell
  • Analyst Count
  • MDWD 1
  • VSTA 2
  • Target Price
  • MDWD $25.00
  • VSTA $3.00
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • VSTA 17.4K
  • Earning Date
  • MDWD 03-20-2025
  • VSTA 03-19-2025
  • Dividend Yield
  • MDWD N/A
  • VSTA N/A
  • EPS Growth
  • MDWD N/A
  • VSTA N/A
  • EPS
  • MDWD N/A
  • VSTA N/A
  • Revenue
  • MDWD $19,720,000.00
  • VSTA $280,865,717.00
  • Revenue This Year
  • MDWD $10.15
  • VSTA $13.03
  • Revenue Next Year
  • MDWD $25.62
  • VSTA $9.88
  • P/E Ratio
  • MDWD N/A
  • VSTA N/A
  • Revenue Growth
  • MDWD N/A
  • VSTA 6.41
  • 52 Week Low
  • MDWD $11.04
  • VSTA $1.60
  • 52 Week High
  • MDWD $24.00
  • VSTA $4.15
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.03
  • VSTA 67.50
  • Support Level
  • MDWD $19.59
  • VSTA $2.69
  • Resistance Level
  • MDWD $20.62
  • VSTA $2.90
  • Average True Range (ATR)
  • MDWD 0.83
  • VSTA 0.16
  • MACD
  • MDWD 0.02
  • VSTA 0.03
  • Stochastic Oscillator
  • MDWD 54.60
  • VSTA 89.20

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

Share on Social Networks: